Cargando…
Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial
PURPOSE: Chloroprocaine provides spinal anesthesia for day-case surgery lasting up to 40 minutes. Intravenous and spinal dexmedetomidine can prolong spinal anesthesia, but no data are available for the combination with chloroprocaine. This double-blind randomized controlled trial compares chloroproc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612665/ https://www.ncbi.nlm.nih.gov/pubmed/34849019 http://dx.doi.org/10.2147/LRA.S324876 |
_version_ | 1784603490500214784 |
---|---|
author | Breebaart, Margaretha B Saerens, Lies Branders, Jordi Casaer, Sari Sermeus, Luc Van Houwe, Patrick |
author_facet | Breebaart, Margaretha B Saerens, Lies Branders, Jordi Casaer, Sari Sermeus, Luc Van Houwe, Patrick |
author_sort | Breebaart, Margaretha B |
collection | PubMed |
description | PURPOSE: Chloroprocaine provides spinal anesthesia for day-case surgery lasting up to 40 minutes. Intravenous and spinal dexmedetomidine can prolong spinal anesthesia, but no data are available for the combination with chloroprocaine. This double-blind randomized controlled trial compares chloroprocaine with spinal or intravenous dexmedetomidine regarding block characteristics, micturition, and discharge times. PATIENTS AND METHODS: After ethical approval and informed consent, 135 patients scheduled for knee arthroscopy were randomized to receive either 40mg spinal chloroprocaine (Chloro-group), 40mg chloroprocaine with 5 mcg spinal dexmedetomidine (Spinal Dex-group) or 40mg chloroprocaine with 0.5 mcg/kg IV dexmedetomidine (IV DEXgroup). Block characteristics, hemodynamic variables and the use of analgesics were registered. Voiding and discharge times were noted. A scoring system was used for micturition problems and sedation. Transient neurological symptoms (TNS) and other late side effects were evaluated after one week. RESULTS: Demographic data were similar between groups. Block onset times and intensity of motor block were comparable between groups. The time to L2 and Bromage 1 regression was prolonged in the SpinalDEx-group by approximately 30 minutes compared to the other groups (p < 0.01). First voiding as well as discharge from the hospital was prolonged in the Spinal Dex-group by approximately 40 minutes p < 0.01. There was no significant difference between groups regarding treatment of hypotension, sedation, micturition problems or the use of postoperative analgesics (P > 0.8). One patient experienced TNS. CONCLUSION: Intrathecal but not intravenous (0.5 mcg/kg) dexmedetomidine can prolong chloroprocaine (40mg) spinal anesthesia when surgery is expected to last over 40 minutes. Despite a similar incidence of adverse effects, this also led to a postponed hospital discharge time. |
format | Online Article Text |
id | pubmed-8612665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86126652021-11-29 Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial Breebaart, Margaretha B Saerens, Lies Branders, Jordi Casaer, Sari Sermeus, Luc Van Houwe, Patrick Local Reg Anesth Clinical Trial Report PURPOSE: Chloroprocaine provides spinal anesthesia for day-case surgery lasting up to 40 minutes. Intravenous and spinal dexmedetomidine can prolong spinal anesthesia, but no data are available for the combination with chloroprocaine. This double-blind randomized controlled trial compares chloroprocaine with spinal or intravenous dexmedetomidine regarding block characteristics, micturition, and discharge times. PATIENTS AND METHODS: After ethical approval and informed consent, 135 patients scheduled for knee arthroscopy were randomized to receive either 40mg spinal chloroprocaine (Chloro-group), 40mg chloroprocaine with 5 mcg spinal dexmedetomidine (Spinal Dex-group) or 40mg chloroprocaine with 0.5 mcg/kg IV dexmedetomidine (IV DEXgroup). Block characteristics, hemodynamic variables and the use of analgesics were registered. Voiding and discharge times were noted. A scoring system was used for micturition problems and sedation. Transient neurological symptoms (TNS) and other late side effects were evaluated after one week. RESULTS: Demographic data were similar between groups. Block onset times and intensity of motor block were comparable between groups. The time to L2 and Bromage 1 regression was prolonged in the SpinalDEx-group by approximately 30 minutes compared to the other groups (p < 0.01). First voiding as well as discharge from the hospital was prolonged in the Spinal Dex-group by approximately 40 minutes p < 0.01. There was no significant difference between groups regarding treatment of hypotension, sedation, micturition problems or the use of postoperative analgesics (P > 0.8). One patient experienced TNS. CONCLUSION: Intrathecal but not intravenous (0.5 mcg/kg) dexmedetomidine can prolong chloroprocaine (40mg) spinal anesthesia when surgery is expected to last over 40 minutes. Despite a similar incidence of adverse effects, this also led to a postponed hospital discharge time. Dove 2021-11-20 /pmc/articles/PMC8612665/ /pubmed/34849019 http://dx.doi.org/10.2147/LRA.S324876 Text en © 2021 Breebaart et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Breebaart, Margaretha B Saerens, Lies Branders, Jordi Casaer, Sari Sermeus, Luc Van Houwe, Patrick Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial |
title | Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial |
title_full | Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial |
title_fullStr | Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial |
title_full_unstemmed | Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial |
title_short | Spinal or Intravenous Dexmedetomidine for Spinal Anesthesia with Chloroprocaine in Ambulatory Knee Arthroscopies: A Double-Blind Randomized Trial |
title_sort | spinal or intravenous dexmedetomidine for spinal anesthesia with chloroprocaine in ambulatory knee arthroscopies: a double-blind randomized trial |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612665/ https://www.ncbi.nlm.nih.gov/pubmed/34849019 http://dx.doi.org/10.2147/LRA.S324876 |
work_keys_str_mv | AT breebaartmargarethab spinalorintravenousdexmedetomidineforspinalanesthesiawithchloroprocaineinambulatorykneearthroscopiesadoubleblindrandomizedtrial AT saerenslies spinalorintravenousdexmedetomidineforspinalanesthesiawithchloroprocaineinambulatorykneearthroscopiesadoubleblindrandomizedtrial AT brandersjordi spinalorintravenousdexmedetomidineforspinalanesthesiawithchloroprocaineinambulatorykneearthroscopiesadoubleblindrandomizedtrial AT casaersari spinalorintravenousdexmedetomidineforspinalanesthesiawithchloroprocaineinambulatorykneearthroscopiesadoubleblindrandomizedtrial AT sermeusluc spinalorintravenousdexmedetomidineforspinalanesthesiawithchloroprocaineinambulatorykneearthroscopiesadoubleblindrandomizedtrial AT vanhouwepatrick spinalorintravenousdexmedetomidineforspinalanesthesiawithchloroprocaineinambulatorykneearthroscopiesadoubleblindrandomizedtrial |